Mylan Pharma Acquisition Ltd. v. Fresenius Kabi USA, LLC
1:15-cv-06700
Overview
Parties
Defendant
Plaintiff
Mylan Pharma Acquisition Ltd. Operating Company
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, N.D. Illinois (ilnd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5866591
Stable formulations of remifentanil
|
Filed: 1997-09-10
Issued: 1999-02-02
|
Expired (Term Ended)
Expires: 2017-09-10
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
78
Dispositive
15
Granted
5
Denied
1
Pending / Review
72
Motions by Category
Key Dispositive Motions & Rulings